Travere Therapeutics Reports First Quarter 2022 Financial Results

SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

Read the full press release >

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

SAN DIEGO , April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Read the full press release >

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >
Fierce Healthcare logo

Coalition of healthcare organizations, experts push forward to improve equity in rare diseases

March 3, 2022 -- Fierce Healthcare featured Eve Dryer, vice president of patient advocacy at Travere Therapeutics, and partners Global Genes and Rare Disease Diversity Coalition in an article about disparities in rare disease care.

Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and the rare community worldwide in recognizing today as Rare Disease Day 2022.

Read the full press release >

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2021 financial results and provided a corporate update.

Read the full press release >

Creating a Better Future for Families Affected by Rare Disease

February 7, 2022 -- With many of our team members impacted by rare disease themselves – our mission at Travere is personal. Read about what inspires our team’s determination to bring life-changing treatment, support and hope to people living with rare disease in this story in Fortune.
PharmaVoice Logo

For the CEO of Travere, running a rare disease company is personal

February 3, 2022 -- This week, PharmaVOICE featured a Q&A with our president and CEO Eric Dube on what it takes to succeed in rare disease. The key takeaway? The people within the company, the science, a patient-inspired culture, humility – and a true passion for making a difference. Read the article >
Life Sciences Voice Top Industry Leaders 2021 logo

In the News: Our president and CEO Eric Dube named Top Industry Leader by Life Sciences Voice

January 27, 2022 -- Eric Dube, president and CEO of Travere Therapeutics, was named a Top Industry Leader for 2021 by Life Sciences Voice. The magazine honored 50 distinguished individuals for this award. Read the article >